A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Slides:

Advertisements

Similar presentations

Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles Ryan G. Steward,

Advertisements

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Krinos M. Trokoudes, M. D. , Constantinos Pavlides, M. Sc

Wendy S. Vitek, M. D. , Jeannine Witmyer, Ph. D. , Sandra A. Carson, M

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.

A giant oocyte in a cohort of retrieved oocytes: does it have any effect on the in vitro fertilization cycle outcome? Ronit Machtinger, M.D., Joseph.

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

Fernando Zegers-Hochschild, M.D. Fertility and Sterility

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Michael M. Alper, M.D. Fertility and Sterility

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Outcomes from a university-based low-cost in vitro fertilization program providing access to care for a low-resource socioculturally diverse urban community

An initial low response predicts poor outcome in in vitro fertilization/intracytoplasmic sperm injection despite improved ovarian response in consecutive.

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study Leonidas Mamas, M.D., Ph.D.

Evaluation of the immature human oocytes from unstimulated cycles in polycystic ovary syndrome patients using a novel scoring system Shan Liu, M.D.,

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Live birth of twins derived from zona-free oocytes

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

A comparison of blood spot vs

Triploidy formation after intracytoplasmic sperm injection may be a surrogate marker for implantation Mitchell P. Rosen, M.D., Shehua Shen, M.D., Anthony.

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Randomized comparison of different ovarian stimulation regimens for assisted reproductive technology in baboons (Papio anubis) Atunga Nyachieo, M.Sc.,

Oocyte cryopreservation

Mitchell P. Rosen, M. D. , Shehua Shen, M. D. , Charles E

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Looking back: egg donors' retrospective evaluations of their motivations, expectations, and experiences during their first donation cycle Nancy J. Kenney,

Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling.

A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization Laura Detti, M.D., Daniel B. Williams, M.D., Jared.

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation Nam D. Tran, M.D., Ph.D., Lusine Aghajanova, M.D.,

Mitchell P. Rosen, M. D. , Erica Johnstone, M. D. , Charles E

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Retrieval of immature oocytes after chemotherapy for Hodgkin's disease and prolonged ovarian down-regulation with gonadotropin-releasing hormone agonist

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Efficiency of changing the embryo transfer time from day 3 to day 2 among women with poor ovarian response: A prospective randomized trial Mustafa Bahceci,

Live babies born per oocyte retrieved in a subpopulation of oocyte donors with repetitive reproductive success J. Ryan Martin, M.D., Jason G. Bromer,

David E. Reichman, M. D. , Stacey A. Missmer, Sc. D. , Katharine F

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Effectiveness of highly purified human menopausal gonadotropin vs

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing

Fertility and Sterility: an evaluation

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Ahmed Badawy, M.D., Aboubakr.

In vitro sildenafil citrate use as a sperm motility stimulant

Krinos M. Trokoudes, M. D. , Constantinos Pavlides, M. Sc

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization Rongrong Tan, M.M.Sc., Danhua Pu,

Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment Daniel Bodri, M.D., M.Sc.,

Presentation transcript:

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran, M.D., Ph.D., A. Musa Zamah, M.D., Ph.D., Marcelle I. Cedars, M.D., Mitchell P. Rosen, M.D. Fertility and Sterility Volume 101, Issue 5, Pages 1308-1314 (May 2014) DOI: 10.1016/j.fertnstert.2014.01.050 Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Outline of conventional estrogen priming and delayed start antagonist controlled ovarian stimulation protocols. CD = cycle day. Fertility and Sterility 2014 101, 1308-1314DOI: (10.1016/j.fertnstert.2014.01.050) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Comparison of percentage of cycles meeting the criteria to proceed to oocyte retrieval in conventional and delayed-start controlled ovarian stimulation cycles. *P=.016. Fertility and Sterility 2014 101, 1308-1314DOI: (10.1016/j.fertnstert.2014.01.050) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions